REGENERON PHARMACEUTICALS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 979.7 USD | +0.61% |
|
+2.10% | +11.44% |
Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Last Days!
Take advantage of the offer
* See conditions on site
| Sales 2024 * | 13.85B 18.94B | Sales 2025 * | 14.95B 20.44B | Capitalization | 105B 144B |
|---|---|---|---|---|---|
| Net income 2024 * | 4.06B 5.55B | Net income 2025 * | 4.47B 6.12B | EV / Sales 2024 * | 6.93 x |
| Net cash position 2024 * | 9.06B 12.39B | Net cash position 2025 * | 14.79B 20.22B | EV / Sales 2025 * | 6.04 x |
| P/E ratio 2024 * |
27.6
x | P/E ratio 2025 * |
24.9
x | Employees | 13,677 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 78.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Regeneron Pharmaceuticals, Inc.
More recommendations
More press releases
More news
| 1 day | +0.58% | ||
| 1 week | +2.10% | ||
| Current month | +9.89% | ||
| 1 month | +8.92% | ||
| 3 months | +4.07% | ||
| 6 months | +22.85% | ||
| Current year | +11.44% |
1 week
952.14
982.58
1 month
875.23982.58
Current year
871.39998.33
1 year
684.81998.33
3 years
492.13998.33
5 years
271.37998.33
10 years
269.50998.33
| Managers | Title | Age | Since |
|---|---|---|---|
| Founder | 64 | 88-01-07 | |
| Chief Executive Officer | 71 | 88-01-07 | |
| Director of Finance/CFO | 54 | 02-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Christine Poon
BRD | Director/Board Member | 71 | 10-11-11 |
| Chief Executive Officer | 71 | 88-01-07 | |
Michael Brown
BRD | Director/Board Member | 82 | 91-05-31 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 7.27% | 0 M€ | 0.00% | - | |
| 7.08% | 0 M€ | 0.00% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-05-13 | 978.7 | +0.51% | 37 750 |
| 24-05-10 | 973.8 | +0.60% | 351,356 |
| 24-05-09 | 968 | +1.28% | 281,949 |
| 24-05-08 | 955.8 | -1.46% | 424,925 |
| 24-05-07 | 970 | +1.18% | 362,320 |
Delayed Quote Nasdaq, May 13, 2024 at 10:24 am
More quotes
Regeneron Pharmaceuticals, Inc. specializes in research, development, producing, and selling drugs used in treating ophthalmologic and inflammatory diseases and cancers. Net sales break down by type of revenue as follows:
- revenues from product sales (56.6%);
- revenues from collaboration agreements (40.4%): collaboration with Sanofi (58.1% of revenues), Bayer (29.1%) and Roche (12.8%);
- other (3%): primarily revenues from sales of technology licenses and subcontracted research services.
At the end of 2022, the group had a portfolio of approximately 35 products in clinical development.
Calendar
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B+
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
25
Last Close Price
973.8
USD
Average target price
1,028
USD
Spread / Average Target
+5.53%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +11.44% | 105B | |
| +4.85% | 109B | |
| -0.26% | 22.25B | |
| -12.10% | 22.09B | |
| -7.91% | 18.68B | |
| -38.36% | 17.58B | |
| -10.16% | 16.85B | |
| +4.58% | 13.76B | |
| +35.75% | 12.46B | |
| +290.87% | 8.12B |
- Stock Market
- Equities
- REGN Stock
